on January 23, 2003
Published online before print January 23, 2003, doi: 10.1161/01.STR.0000053029.45352.A0
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 3, 2002
From the Departments of Epidemiology (S.B., K.C., D.G.) and Clinical Pharmacology (M.A., J.H.), Institute of Public Health, University of Southern Denmark, Odense, Denmark; Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain (L.A.G.R.); and Department of Neurology, Odense University Hospital, Odense, Denmark (S.B., I.T., D.G.). * To whom correspondence should be addressed. E-mail: dgaist{at}health.sdu.dk.
Background and Purpose--Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with bleeding complications and may affect the risk of hemorrhagic stroke through inhibition of platelet cyclooxygenase-1. We performed a population-based case-control study to estimate the risk of intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke in users of NSAIDs. Methods--We used a population-based patient registry to identify all patients with a first-ever stroke discharge diagnosis in the period of 1994 to 1999. All diagnoses were validated according to predefined criteria. We selected 40 000 random controls from the background population. Information on drug use for cases and controls was retrieved from a prescription registry. Odds ratios were adjusted for age, sex, calendar year, and use of other medication. To evaluate the effect of various potential confounders not recorded in the register, we performed separate analyses on data from 2 large population-based surveys with more detailed information on risk factors. Results--The cases were classified as intracerebral hemorrhage (n=659), subarachnoid hemorrhage (n=208), and ischemic stroke (n=2717). The adjusted odds ratio of stroke in current NSAID users compared with never users was 1.2 (95% CI, 0.9 to 1.6) for intracerebral hemorrhage, 1.2 (95% CI, 0.7 to 2.1) for subarachnoid hemorrhage and 1.2 (95% confidence interval, 1.0 to 1.4) for ischemic stroke. The survey data indicated that additional confounder control would not have led to an increase in relative risk estimates. Conclusions--Current exposure to NSAIDs is not a risk factor for intracerebral hemorrhage or subarachnoid hemorrhage. Furthermore, NSAIDs probably offer no protection against first-ever ischemic stroke.
Accepted on September 9, 2002
Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs. A Nested Case-Control Study
Søren Bak MD;
Key words: anti-inflammatory agents, nonsteroidal • stroke • stroke, hemorrhagic
This article has been cited by other articles:
 |
|
 |
|
  C. L. Roumie, E. F. Mitchel Jr, L. Kaltenbach, P. G. Arbogast, P. Gideon, and M. R. Griffin Nonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke Stroke, July 1, 2008; 39(7): 2037 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. M. Haag, M. J. Bos, A. Hofman, P. J. Koudstaal, M. M. B. Breteler, and B. H. C. Stricker Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke Arch Intern Med, June 9, 2008; 168(11): 1219 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.-K. Choi, B.-J. Park, S.-W. Jeong, K.-H. Yu, and B.-W. Yoon Nonaspirin Nonsteroidal Anti-inflammatory Drugs and Hemorrhagic Stroke Risk: The Acute Brain Bleeding Analysis Study Stroke, March 1, 2008; 39(3): 845 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Waksman, A. Brody, and S. D Phillips Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe? Ann. Pharmacother., July 1, 2007; 41(7): 1163 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. McGettigan and D. Henry Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 JAMA, October 4, 2006; 296(13): 1633 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Chan, J. E. Manson, C. M. Albert, C. U. Chae, K. M. Rexrode, G. C. Curhan, E. B. Rimm, W. C. Willett, and C. S. Fuchs Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events Circulation, March 28, 2006; 113(12): 1578 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Blankfield Can Natriuretic Peptide Levels Predict the Cardiovascular Complications of COX-2 Inhibitors and Nonsteroidal Anti-inflammatory Drugs? J Am Board Fam Med, March 1, 2006; 19(2): 178 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cipollone, B. Rocca, and C. Patrono Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 246 - 255. [Abstract] [Full Text]
|
|
|
|
|
|
S. Juvela, D. Gaist, S. Bak, S. P. Johnsen, L. Pedersen, H. T. Sorensen, S. Friis, J. H. Olsen, W. J. Blot, and J. K. McLaughlin Nonsteroidal Anti-Inflammatory Drugs as Risk Factors for Spontaneous Intracerebral Hemorrhage and Aneurysmal Subarachnoid Hemorrhage * Response Stroke, June 1, 2003; 34 (6): e34 - e36. [Full Text] [PDF]
|
|
|
|
|
|
S. Bak, M. Andersen, I. Tsiropoulos, L. A. Garcia Rodriguez, J. Hallas, K. Christensen, D. Gaist, and A. I. Qureshi Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nested Case-Control Study * Editorial Comment Stroke, February 1, 2003; 34(2): 379 - 386. [Abstract] [Full Text] [PDF]
|
|